Last updated: February 20, 2026
What is the Product?
The National Drug Code (NDC) 68001-0130 refers to Ruxolitinib (Jakafi), a Janus kinase (JAK) inhibitor used primarily to treat myelofibrosis and polycythemia vera. Approved by the FDA in 2011, it has gained prominence for its targeted mechanism of action in myeloproliferative neoplasms.
Market Overview
Indications and Market Size
| Indication |
Market Size (2019-2022) |
Estimated Growth CAGR (2023-2028) |
Key Drivers |
| Myelofibrosis |
4,500-5,500 patients in US |
6% annually |
Increasing diagnosis rate, expanding insurance coverage |
| Polycythemia Vera |
10,000-12,000 patients |
5.5% annually |
Improved diagnostic criteria, off-label use |
Source: IQVIA, 2022; CDC reports, 2022
Competitive Landscape
| Competitors |
Market Share (2022) |
Notable Features |
| Fedratinib (Inrebic) |
20% |
Second-generation JAK inhibitor |
| Momelotinib |
10-15% |
Under clinical development |
| Jakafi (Ruxolitinib) |
65-70% |
First-in-class, FDA-approved |
Patent and Exclusivity Status
- Patent protection expired in 2019 for the core molecule.
- Biogen and Incyte hold data exclusivity until 2024, limiting biosimilar entry until then.
- Patent litigation and biosimilar developments are ongoing.
Current Pricing and Cost Analysis
Wholesale Acquisition Cost (WAC)
| Price Component |
2023 Price |
Notes |
| Per 30-day supply |
$13,200 |
Based on average dosing (20-30 mg twice daily) |
| Per year |
~$158,400 |
Calculated for standard dosing |
Reimbursement Environment
| Payer Type |
Coverage Status |
Reimbursement Rate |
Notes |
| Medicare |
Full coverage |
80-90% |
Subject to formulary status |
| Commercial |
Variable |
70-90% |
Negotiated discounts apply |
| Medicaid |
Limited |
70-80% |
May include supplemental rebates |
Discounted and Negotiated Pricing
- Average net price (post-rebate): $10,000 - $11,000 per month.
- Biosimilar competition expected post-2024 could reduce prices by 20-30%.
Price Projections (2023-2030)
| Year |
Projected Price (monthly) |
Assumptions |
Key Factors |
| 2023 |
$10,500 |
Current rebates and discounts |
Stable demand, regulatory status unchanged |
| 2025 |
$8,500 |
Biosimilar entry begins |
20%-30% price decline |
| 2027 |
$7,500 |
Increased biosimilar penetration |
Market saturation, price competition intensifies |
| 2030 |
$6,500 |
Full biosimilar uptake, price stabilization |
Persistent cost pressure |
Market Drivers for Price Changes
- Biosimilar approvals and entry expected to begin post-2024.
- Label expansions potentially increasing volume.
- Payer negotiations lowering net prices.
- Patent and data exclusivity expiration influencing pricing.
Commercial and Regulatory Trends
- Regulatory pathways: The FDA facilitates biosimilar approval via 351(k) pathway.
- Market access: Companies will seek formulary inclusions through value demonstrations.
- Pricing trends: Historically, biologics and targeted therapies face price declines with biosimilar entry.
Conclusion
The current market for NDC 68001-0130 (Ruxolitinib) is characterized by high prices driven by patent protection and limited biosimilar options. Post-2024 biosimilar entry will exert downward pressure, with prices potentially decreasing by up to 30% over five years. Revenue growth will depend on indications expansion, improved market penetration, and the competitive landscape's evolution.
Key Takeaways
- Ruxolitinib's current annual revenue in the US exceeds $2 billion.
- Price projections suggest gradual reductions starting in 2025 driven by biosimilar competition.
- Market growth hinges on increased diagnosis rates and label expansions.
- Reimbursement remains favorable but is subject to payer negotiations.
- Ongoing patent and regulatory developments will shape the competitive landscape.
FAQs
1. When will biosimilars for Ruxolitinib likely enter the market?
Biosimilar applications are expected to be filed around 2023-2024, with market entry potentially in 2025-2026.
2. How will biosimilar entry affect current prices?
Biosimilar entry could result in price reductions of 20-30% over three to five years as competition increases.
3. What are the key indications for Ruxolitinib?
Primary indications include myelofibrosis and polycythemia vera; expanded use in graft-versus-host disease is also anticipated.
4. What factors could alter the market projection?
Regulatory delays, patent litigation, faster biosimilar approval, or new therapeutic alternatives could affect pricing and market share.
5. How does Ruxolitinib compare to competing treatments?
It holds approximately 65-70% market share due to FDA approval and established clinical efficacy. Second-generation inhibitors target similar indications, potentially impacting future market dynamics.
References
[1] IQVIA. (2022). Pharmaceutical Market Reports.
[2] CDC. (2022). Myeloproliferative Neoplasms Data.
[3] FDA. (2011). Ruxolitinib NDA Approval.
[4] U.S. Patent and Trademark Office. (2019). Patent Expiry Notices.
[5] Medtrack and Pink Sheet Reports. (2023). Biotech Market Trends.
